Newsroom

Sorted by: Latest

-

Neuberger and KKR to Invest in Datavant Alongside New Mountain Capital

NEW YORK--(BUSINESS WIRE)--Datavant, the data collaboration platform trusted for healthcare, New Mountain Capital, Neuberger, and KKR today announced that funds managed by Neuberger Capital Solutions, along with Neuberger Private Markets (collectively, “Neuberger”), and investment funds and accounts managed by KKR have agreed to acquire a significant minority stake in Datavant (the “Company”). New Mountain Capital (“New Mountain”), which has been an investor in Datavant since 2014, will retain i...
-

Cebreo Medical Receives CE Mark for NeuroBuds®, a Discreet In-Ear, Medical-Grade EEG Wearable for Extended Ambulatory Monitoring

ALLERØD, Denmark--(BUSINESS WIRE)--Cebreo Medical's NeuroBuds has received CE marking, allowing the in-ear EEG wearable to be sold across the European Union....
-

D-Wave to Showcase Unique Dual-Platform Quantum Computing at Quantum World Congress 2026

PALO ALTO, Calif.--(BUSINESS WIRE)--D-Wave Quantum Inc. (NASDAQ: QBTS) (“D-Wave” or the “Company”), the only dual-platform quantum computing company providing both annealing and gate-model systems, software and services, today announced its participation as a platinum sponsor of Quantum World Congress 2026, taking place September 23-25 in College Park, Maryland. At Quantum World Congress, D-Wave will demonstrate that the quantum era is multi-platform with different quantum computing technologie...
-

PMG Extends Case Central® to CFPB Complaints Management

ATLANTA--(BUSINESS WIRE)--PMG.net, Inc. today announced that it is extending Case Central®, its case management platform for data furnishers, to handle CFPB consumer complaints alongside credit reporting disputes within a single system. The extension follows the Consumer Financial Protection Bureau’s June 24 announcement of a broad overhaul of its consumer complaint system. The announcement also stated that credit reporting complaints had risen from roughly 150,000 in 2019 to more than five mil...
-

Elvinix Secures Exclusive License to Advance Novel Peptide Therapy Aimed at Restoring Insulin Production in Type 1 Diabetes

DOVER, Del.--(BUSINESS WIRE)--Elvinix secures exclusive license to Zealand Pharma's GLP-1/gastrin dual-agonist peptides to develop a regenerative therapy for type 1 diabetes....
-

Pebblebrook Hotel Trust Declares Dividends for Third Quarter 2026

BETHESDA, Md.--(BUSINESS WIRE)--Pebblebrook Hotel Trust Declares Dividends for Third Quarter 2026...
-

Massachusetts Financial Services Company UK Regulatory Announcement: Form 8.3 SEGRO plc

LONDON--(BUSINESS WIRE)--  FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE Rule 8.3 of the Takeover Code (the “Code”) 1. KEY INFORMATION (a) Full name of discloser: Massachusetts Financial Services Company (b) Owner or controller of interests and short positions disclosed, if different from 1(a): The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiari...
-

Rockwell Automation Joins Anthropic’s Project Glasswing to Advance AI-Enabled Cyber Defense for Industrial Critical Infrastructure

MILWAUKEE--(BUSINESS WIRE)--Rockwell Automation, Inc. (NYSE:ROK), the world’s largest company dedicated to industrial automation and digital transformation, today announced it has joined Anthropic’s Project Glasswing, a global initiative designed to help secure the world’s most critical software and strengthen cyber resilience across critical infrastructure.Through controlled access to Claude Mythos 5, Rockwell security teams are exploring ways to accelerate the discovery, validation, prioritiza...
-

Rocket Pharmaceuticals Announces FDA Alignment on Path to Complete Pivotal Phase 2 Trial of RP-A501 in Danon Disease

CRANBURY, N.J.--(BUSINESS WIRE)--Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a fully integrated, commercial-stage biotechnology company advancing genetic medicines for rare and life-threatening diseases, focused on inherited cardiovascular disorders, today announced alignment with the U.S. Food and Drug Administration (FDA) on continued enrollment and dosing and key elements of the global pivotal Phase 2 trial of RP-A501 for the treatment of Danon disease, including the recalibrated dose, 12-p...
-

Yukon Partners Announces Promotion of Nathan Weekly to Director

MINNEAPOLIS--(BUSINESS WIRE)--Yukon Partners is pleased to announce the promotion of Nathan Weekly to Director....